Skip to main navigation Skip to search Skip to main content

Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patients (Pts) with High-Risk (HR) Multiple Myeloma (MM)

  • Guenther Koehne
  • , Sean Devlin
  • , Neha Korde
  • , Sham Mailankody
  • , Landau Heather
  • , Hani Hassoun
  • , Alexander Lesokhin
  • , Nikoletta Lendvai
  • , David Chung
  • , Nicholas Sarlis
  • , Sergio Giralt
  • , Ola Landgren

Research output: Contribution to conferencePresentation

Original languageAmerican English
DOIs
StatePublished - Jan 9 2017
EventClinical Lymphoma, Myeloma & Leukemia -
Duration: Jan 9 2017 → …

Conference

ConferenceClinical Lymphoma, Myeloma & Leukemia
Period1/9/17 → …

Disciplines

  • Medicine and Health Sciences
  • Immunology and Infectious Disease

Cite this